Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May;21(5):597-598.
doi: 10.1016/S1473-3099(21)00194-8.

Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens

Jacob E Choby  1 , Tugba Ozturk  1 , Sarah W Satola  2 , Jesse T Jacob  2 , David S Weiss  3
Affiliations
Comment

Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens

Jacob E Choby et al. Lancet Infect Dis. 2021 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

DSW reports grants from National Institutes of Health, Veterans Health Administration, and Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease award. DSW also has a pending patent for exploitation of heteroresistance for combination therapy. JTJ reports grants from Centers for Disease Control and Prevention. JEC reports grants from the Cystic Fibrosis Foundation and National Institutes of Health (T32 DK108735). All other authors declare no competing interests. We would like to thank the Georgia Emerging Infections Program led by Monica Farley, and its Multi-Site Gram-negative Surveillance Initiative, as well as the Emory Antibiotic Resistance Center's Investigational Clinical Microbiology Core, for providing isolates. This work was supported by the National Institutes of Health (AI141883, AI148661, AI158080) and the Department of Veteran's Affairs (BX002788). The Georgia Emerging Infections Program and the Multi-Site Gram-negative Surveillance Initiative are funded by the Centers for Disease Control and Prevention.

Comment in

Comment on

References

    1. Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2021; 21: 226–40. - PubMed
    1. Band VI, Satola SW, Smith RD, et al. Colistin heteroresistance is largely undetected among carbapenem-resistant Enterobacterales in the United States. mBio 2021; 12: e02881–20. - PMC - PubMed
    1. Band VI, Crispell EK, Napier BA, et al. Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae. Nat Microbiol 2016; 1: 16053. - PMC - PubMed
    1. Band VI, Satola SW, Burd EM, Farley MM, Jacob JT, Weiss DS. Carbapenem-resistant Klebsiella pneumoniae exhibiting clinically undetected colistin heteroresistance leads to treatment failure in a murine model of infection. mBio 2018; 9: e02448–17. - PMC - PubMed
    1. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother 2018; 62: e01968–17. - PMC - PubMed

LinkOut - more resources